PTC Therapeutics, Inc. (PTCT)
NASDAQ: PTCT · Real-Time Price · USD
68.40
+5.58 (8.88%)
At close: Mar 9, 2026, 4:00 PM EDT
68.60
+0.20 (0.29%)
After-hours: Mar 9, 2026, 5:32 PM EDT
PTC Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Cash & Equivalents | 984.65 | 779.71 | 594 | 279.83 | 189.72 | Upgrade
|
| Short-Term Investments | 960.72 | 373.75 | 288.81 | 130.87 | 583.66 | Upgrade
|
| Cash & Short-Term Investments | 1,945 | 1,153 | 882.81 | 410.71 | 773.38 | Upgrade
|
| Cash Growth | 68.66% | 30.66% | 114.95% | -46.89% | -29.93% | Upgrade
|
| Receivables | 181.62 | 158.55 | 261.02 | 155.61 | 110.46 | Upgrade
|
| Inventory | 79.65 | 23.19 | 30.58 | 21.81 | 15.86 | Upgrade
|
| Prepaid Expenses | 58.51 | 22.93 | 41.62 | 105.66 | 54.68 | Upgrade
|
| Other Current Assets | 8.8 | 7.4 | 2.6 | - | - | Upgrade
|
| Total Current Assets | 2,274 | 1,366 | 1,219 | 693.79 | 954.37 | Upgrade
|
| Property, Plant & Equipment | 135.42 | 117.66 | 178.99 | 175.02 | 130.01 | Upgrade
|
| Long-Term Investments | - | - | - | - | 21 | Upgrade
|
| Goodwill | 82.34 | 82.34 | 82.34 | 82.34 | 82.34 | Upgrade
|
| Other Intangible Assets | 388.75 | 118.79 | 379.5 | 705.89 | 724.84 | Upgrade
|
| Other Long-Term Assets | 18.3 | 20.7 | 36.25 | 48.58 | 25.5 | Upgrade
|
| Total Assets | 2,899 | 1,705 | 1,896 | 1,706 | 1,938 | Upgrade
|
| Accounts Payable | 45.49 | 17.27 | 6.05 | 27.27 | 23.03 | Upgrade
|
| Accrued Expenses | 314.64 | 261.72 | 366.26 | 276.33 | 251.83 | Upgrade
|
| Current Portion of Long-Term Debt | 569.63 | 257.82 | 194.31 | 72.15 | 208.83 | Upgrade
|
| Current Portion of Leases | 15.48 | 13.36 | 16 | 12.37 | 10.27 | Upgrade
|
| Current Income Taxes Payable | 4.68 | 4.7 | - | 4.71 | 1.29 | Upgrade
|
| Current Unearned Revenue | 2.04 | 5.51 | 0.8 | 1.35 | - | Upgrade
|
| Other Current Liabilities | 16.47 | 20.6 | 19.67 | 12.05 | 14.1 | Upgrade
|
| Total Current Liabilities | 968.43 | 580.98 | 603.1 | 406.24 | 509.35 | Upgrade
|
| Long-Term Debt | 2,025 | 2,109 | 1,904 | 1,257 | 956.59 | Upgrade
|
| Long-Term Leases | 96.58 | 90.52 | 114.81 | 119.54 | 93.67 | Upgrade
|
| Long-Term Deferred Tax Liabilities | - | - | 55.91 | 102.83 | 137.11 | Upgrade
|
| Other Long-Term Liabilities | 13.7 | 22.23 | 36.44 | 166.64 | 239.9 | Upgrade
|
| Total Liabilities | 3,104 | 2,803 | 2,714 | 2,053 | 1,937 | Upgrade
|
| Common Stock | 0.08 | 0.08 | 0.08 | 0.07 | 0.07 | Upgrade
|
| Additional Paid-In Capital | 2,748 | 2,575 | 2,466 | 2,305 | 2,124 | Upgrade
|
| Retained Earnings | -2,964 | -3,647 | -3,284 | -2,657 | -2,098 | Upgrade
|
| Comprehensive Income & Other | 10.5 | -25.89 | -1.29 | 4.8 | -24.28 | Upgrade
|
| Shareholders' Equity | -205.31 | -1,098 | -818.56 | -347.09 | 1.44 | Upgrade
|
| Total Liabilities & Equity | 2,899 | 1,705 | 1,896 | 1,706 | 1,938 | Upgrade
|
| Total Debt | 2,707 | 2,471 | 2,229 | 1,462 | 1,269 | Upgrade
|
| Net Cash (Debt) | -761.69 | -1,318 | -1,346 | -1,051 | -495.99 | Upgrade
|
| Net Cash Per Share | -8.63 | -17.15 | -17.99 | -14.65 | -7.04 | Upgrade
|
| Filing Date Shares Outstanding | 82.77 | 78.87 | 76.61 | 73.82 | 71.36 | Upgrade
|
| Total Common Shares Outstanding | 81.47 | 77.7 | 75.71 | 73.1 | 70.83 | Upgrade
|
| Working Capital | 1,306 | 784.55 | 615.53 | 287.55 | 445.02 | Upgrade
|
| Book Value Per Share | -2.52 | -14.13 | -10.81 | -4.75 | 0.02 | Upgrade
|
| Tangible Book Value | -676.41 | -1,299 | -1,280 | -1,135 | -805.74 | Upgrade
|
| Tangible Book Value Per Share | -8.30 | -16.72 | -16.91 | -15.53 | -11.38 | Upgrade
|
| Machinery | 64.4 | 59.76 | 84.19 | 66.64 | 50.8 | Upgrade
|
| Construction In Progress | 2.8 | 3.03 | 24.01 | 14.35 | 9.02 | Upgrade
|
| Leasehold Improvements | 35.16 | 31.53 | 30.17 | 28.97 | 19.94 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.